Cargando…
Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been reported. A pathogenic role of MMP-3 in other...
Autores principales: | Luckman, Steven P., Gilhus, Nils Erik, Romi, Fredrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150147/ https://www.ncbi.nlm.nih.gov/pubmed/21826262 http://dx.doi.org/10.4061/2011/151258 |
Ejemplares similares
-
Myasthenia Gravis: A Review of Available Treatment Approaches
por: Gilhus, Nils Erik, et al.
Publicado: (2011) -
Repeated Acetylcholine Receptor Antibody-Concentrations and Association to Clinical Myasthenia Gravis Development
por: Heldal, Anne Taraldsen, et al.
Publicado: (2014) -
Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011) -
Advances and challenges in the treatment of myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2021) -
Immunoactive treatment for myasthenia gravis; a Chinese experience
por: Gilhus, Nils Erik
Publicado: (2020)